# Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage

Study · id `cardio:ct-nct04849000` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04849000](<https://clinicaltrials.gov/study/NCT04849000>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04849000

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 709 participants.

## Technical summary

Registry record NCT04849000. Randomized; quadruple masking; primary purpose treatment. Start 2021-04-23 (actual); primary completion 2022-06-21 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 709 participants (enrolled count; ClinicalTrials.gov record NCT04849000, source copy `cardio:ctgov-nct04849000-2023-05-19`, retrieved 2026-10-31)
- Started: 2021-04-23 (actual) (ClinicalTrials.gov record NCT04849000, source copy `cardio:ctgov-nct04849000-2023-05-19`, retrieved 2026-10-31)
- Primary completion: 2022-06-21 (actual) (ClinicalTrials.gov record NCT04849000, source copy `cardio:ctgov-nct04849000-2023-05-19`, retrieved 2026-10-31)
- Completion: 2023-01-13 (actual) (ClinicalTrials.gov record NCT04849000, source copy `cardio:ctgov-nct04849000-2023-05-19`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT04849000, source copy `cardio:ctgov-nct04849000-2023-05-19`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04849000-2023-05-19`, retrieved 2026-10-31)

## The registry's words

- Brief title: Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage
- Condition: Primary Hypercholesterolemia
- Condition: Mixed Hyperlipemia
- Intervention (Drug): SHR-1209
- Intervention (Drug): SHR-1209 Placebo
- Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)
- Registry lists this organization as the lead sponsor: Jiangsu HengRui Medicine Co., Ltd. (`cardio:org-jiangsu-hengrui-medicine-co-ltd`)

## Provenance

Content hash: 3cbd5a0091a5801a303a43536e17a58ea1cadc4e75a9557a38213d2162f55d68
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
